STOCK TITAN

Medicenna Reports More than Doubling of Median Overall Survival in Glioblastoma Patients With Unresectable Recurrent IDH-WT Tumors Following One Treatment with Bizaxofusp Versus a Matched External Control at SNO 2026

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Medicenna Therapeutics (MDNAF) reported longer median overall survival with bizaxofusp in a Phase 2b subgroup compared with matched external controls.

Among 19 patients with unresectable recurrent glioblastoma, confirmed IDH-wildtype tumors and doses of at least 180 micrograms, median survival was 13.7 versus 6.2 months (p=0.013). Twelve-month survival was 52.6% versus 15.6%; 24-month survival was 26.3% versus 6.7%. Median survival also favored bizaxofusp in the broader IDH-wildtype population and full per-protocol population. The retrospective, non-randomized comparison remains susceptible to residual confounding and requires randomized confirmation.

Medicenna proposes a hybrid Phase 3 trial using a single 240-microgram dose, approximately 200 randomized patients and an external control supplement. The FDA agreed that a randomized standard-of-care arm supplemented by eligibility-matched external controls was feasible.

Loading...
Loading translation...
8 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointHigh-dose IDH-wildtype subgroup (N=19) achieved median survival of 13.7 versus 6.2 months with external controls (p=0.013).
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Proposed Phase 3 would test a single 240-microgram dose, the established maximum tolerated dose, with overall survival as primary endpoint.
  • Moderate pointFDA agreed that supplementing a randomized standard-of-care arm with eligibility-matched external controls was feasible.
  • Minor pointTwelve-month survival in the high-dose subgroup was 52.6% versus 15.6% with external controls.
  • Minor pointTwenty-four-month survival in the high-dose subgroup was 26.3% versus 6.7% with external controls.
3 minor points
  • Minor pointBroader IDH-wildtype population (N=37), including low doses, had median survival of 12.5 versus 7.3 months.
  • Minor pointFull per-protocol population (N=44), including unknown IDH status and low doses, had median survival of 12.5 versus 7.2 months.
  • Minor pointHigh-dose comparison balanced 10 prognostic factors, with all factors and the propensity score showing standardized differences below 0.10.

Negative

  • Moderate pointPhase 3-relevant evidence rests on a small, 19-patient subgroup.
  • Moderate pointRetrospective external-control comparisons remain susceptible to residual confounding and are not a substitute for randomized evidence.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Median overall survival (mOS) was 13.7 months with a single high-dose treatment with bizaxofusp vs. 6.2 months for an eligibility-matched and propensity score-balanced external control arm (ECA) in a Phase 3 relevant unresectable IDH-wildtype recurrent glioblastoma (rGBM) patients (N = 19, HR 0.499; p=0.013)

Survival favored bizaxofusp with statistical significance versus ECA across the full per-protocol (N=44, mOS =12.5 vs 7.2 months) and WHO-aligned IDH-wildtype (N = 37; mOS = 12.5 vs 7.3 months; HR 0.621; p=0.023) populations, including all patients who received low dose of bizaxofusp

Propensity score weighting achieved strong balance across 10 established prognostic factors, supporting the planned hybrid randomized Phase 3 design

TORONTO and HOUSTON, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company developing Superkines™ for cancer and autoimmune disease, today announced new clinical results from the Phase 2b study of bizaxofusp (formerly MDNA55) in patients with unresectable recurrent glioblastoma (rGBM). The data were presented during an oral session at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO 2026), held in Philadelphia from 12-15 November, 2026.

The presentation, titled "Survival outcomes with bizaxofusp (MDNA55) in unresectable IDH-wildtype recurrent glioblastoma (rGBM) using a propensity score-weighted external control arm (ECA) in the intended Phase 3 population," was delivered by Nicholas A. Butowski, MD, Professor of Neurological Surgery and Director of Translational Research, Neuro-Oncology at the University of California, San Francisco.

"These results provide important evidence that further strengthens the potential of bizaxofusp for patients with unresectable recurrent glioblastoma, a population with few effective treatment options and a median survival of six to seven months," said Fahar Merchant, PhD, President and Chief Executive Officer of Medicenna. "Most importantly, the magnitude of the observed survival effect was greatest in the patient population that most closely reflects our planned Phase 3 treatment strategy, where median overall survival more than doubled compared with a stringently matched and independently analyzed external control. Together with our prior discussions with the FDA, these results further strengthen the clinical rationale for advancing bizaxofusp toward a pivotal study using a hybrid randomized Phase 3 design. We look forward to advancing bizaxofusp’s development in collaboration with potential partners."

The external control analysis included 80 eligibility-matched records obtained from patient registries at UCSF and St. Michael's Hospital, including 79 patients with confirmed IDH-wildtype disease. Overall survival was measured from the same clinical index date in both the bizaxofusp and external-control populations, and propensity score weighting was re-estimated for each comparison. The Phase 3-relevant comparison is based on a small subgroup (N=19). Retrospective external-control comparisons remain susceptible to residual confounding and are not a substitute for randomized evidence.

"Recurrent glioblastoma remains extremely challenging to treat, particularly for patients who are not candidates for repeat surgery," said Dr. Butowski. "The survival difference observed with bizaxofusp relative to a carefully matched external control is encouraging, particularly in the high-dose IDH-wildtype group that most closely reflects the intended Phase 3 population. This is a non-randomized comparison in a small number of patients and needs to be confirmed, but these findings provide a strong rationale to evaluate bizaxofusp prospectively in a randomized pivotal study."

Key Findings Presented at SNO 2026

  • Median overall survival was more than twice that of the external control in the Phase 3-relevant population.
  • Among confirmed IDH-wildtype patients treated with at least 180 micrograms of bizaxofusp (N=19), mOS was 13.7 months compared with 6.2 months for the eligibility-matched and propensity score-balanced ECA (HR 0.499; 95% CI: 0.278-0.895; p=0.013). Twelve-month survival was 52.6% with bizaxofusp compared with 15.6% for the ECA, while 24-month survival was 26.3% compared with 6.7%, respectively.
  • The survival difference favoring bizaxofusp was maintained in the broader WHO-aligned IDH-wildtype population. In all confirmed IDH-wildtype patients in the per-protocol population (N=37), mOS was 12.5 months with bizaxofusp compared with 7.3 months for the ECA (HR 0.625; 95% CI: 0.393-0.993; p=0.043), including patients receiving low doses of bizaxofusp (< 180 micrograms)
  • A consistent survival difference was observed in the per-protocol population (N=44), where mOS was 12.5 months with bizaxofusp compared with 7.2 months for the ECA (HR 0.621; 95% CI: 0.413-0.934; p=0.023), including patients with unknown IDH status and low dose cohorts
  • Propensity score weighting achieved strong balance between treatment and control populations. The external control analysis balanced patients across 10 established prognostic factors in recurrent GBM, including age, sex, performance status, MGMT promoter methylation, time to relapse, prior relapses, extent of initial resection, tumor size and location at relapse, and steroid use. In the Phase 3-relevant comparison, all prognostic factors and the propensity score had absolute standardized differences below 0.10, demonstrating negligible measured baseline imbalance between the bizaxofusp arm and ECA.
  • Results support the planned Phase 3 dose and patient population. The high-dose analysis included an IL-4R-unselected population of patients with confirmed IDH-wildtype disease receiving at least 180 micrograms of bizaxofusp. The planned Phase 3 dose is 240 micrograms, the established maximum tolerated dose.

Proposed Phase 3 Study

Medicenna's proposed pivotal study will evaluate a single 240 microgram dose of bizaxofusp administered by convection-enhanced delivery (CED) in patients with unresectable, confirmed IDH-wildtype recurrent glioblastoma at first or second recurrence.

The proposed hybrid design incorporates approximately 200 randomized patients, with approximately 150 patients receiving bizaxofusp and approximately 50 receiving standard-of-care therapy. The randomized standard-of-care arm would be supplemented by an approximately 100-patient-equivalent contemporaneous, eligibility-matched and propensity score-weighted external control arm. The primary endpoint is overall survival versus the hybrid control arm.

At an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), the Agency agreed that a randomized standard-of-care arm supplemented by an eligibility-matched external control arm was a feasible approach for the planned pivotal study. No IL-4R companion diagnostic is planned for Phase 3 eligibility, enabling enrollment irrespective of tumor IL-4R expression.

The presentation will be available on the Scientific Presentations section of Medicenna's investor relations website. .

About Bizaxofusp

Bizaxofusp (formerly MDNA55) is Medicenna's IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in unresectable recurrent glioblastoma. Bizaxofusp is designed to selectively target the interleukin-4 receptor (IL-4R), which is overexpressed by glioblastoma cells and cells in the tumor microenvironment, and is administered directly into the tumor using convection-enhanced delivery. Bizaxofusp has received Fast Track designation from the U.S. Food and Drug Administration and Orphan Drug designation in the United States and Europe.

About Medicenna Therapeutics

Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer and autoimmune diseases. Medicenna is advancing MDNA11, a long-acting IL-2 Superkine designed to selectively activate cancer-fighting immune cells, which is currently being evaluated in the Phase 1/2 ABILITY-1 study and the Phase 1b NEO-CYT study. The Company is also developing MDNA113, a targeted PD-1 x IL-2 bifunctional immunotherapy for solid tumors, and MDNA209, an antagonist of CD122 blocking IL-2/IL-15 signaling, using its proprietary BiSKIT and T-MASK platforms. The Company's most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. Bizaxofusp has received Fast Track designation from the FDA, and Orphan Drug designation from the FDA and orphan designation in the EU.

For more information, visit www.medicenna.com, and follow us on X and LinkedIn.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements regarding the continued clinical development and potential therapeutic benefits of bizaxofusp; plans to advance bizaxofusp toward a pivotal Phase 3 trial; the proposed design, dose, patient population and endpoints of a future Phase 3 study; potential future regulatory interactions; potential development or financing partnerships; and the Company's future operations, plans, objectives and expectations. Forward-looking statements are subject to risks and uncertainties, and actual results and future events could differ materially from those anticipated. Important factors that could cause actual results to differ materially from the Company's expectations include the risks detailed in the Company's latest annual information form and other filings with applicable securities regulators.

The reader is cautioned that assumptions used in the preparation of forward-looking information may prove to be incorrect. Actual results may differ materially from those predicted as a result of known and unknown risks, uncertainties and other factors. Readers should not place undue reliance on forward-looking information. Forward-looking statements are made as of the date hereof and, except as required by law, the Company does not intend and does not assume any obligation to update or revise them.

This news release contains hyperlinks to information that is not deemed to be incorporated by reference in this news release.

Investor and Company Contact

Daniel Scarr
Director, Corporate Development
Medicenna Therapeutics
ir@medicenna.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What survival results did Medicenna report for bizaxofusp in recurrent glioblastoma?

Median overall survival was 13.7 months versus 6.2 months for matched external controls among 19 patients with confirmed IDH-wildtype tumors receiving at least 180 micrograms. The comparison was non-randomized and retrospective, so the findings require confirmation in randomized research.

How would Medicenna's proposed Phase 3 bizaxofusp trial be designed?

The proposed trial would randomize approximately 200 patients: approximately 150 to bizaxofusp and approximately 50 to standard-of-care therapy. The standard-of-care arm would be supplemented by an approximately 100-patient-equivalent contemporaneous, eligibility-matched and propensity score-weighted external control arm. Overall survival versus the hybrid control arm would be the primary endpoint.

Who would be eligible for Medicenna's proposed Phase 3 bizaxofusp study, and how would treatment be given?

The proposed study would enroll patients with unresectable, confirmed IDH-wildtype recurrent glioblastoma at first or second recurrence. A single 240-microgram dose would be administered by convection-enhanced delivery. No IL-4R companion diagnostic is planned, allowing enrollment irrespective of tumor IL-4R expression.

Keep reading